Neurokinin receptor antagonists

Bibliography

• ELLIOTT J, SEWARD EM: Neurokinin receptor antago- nists. Exp. Opin. Ther. Patents (1997) 7(0:43–54.
   Google Scholar
• ••A very good recent review of neuokinin antagonists.
   Google Scholar
• SHEPHEARD SL, WILLIAMSON DJ, HILL RG, HARGREAVES RJ: The non-peptide neurokinini receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats. Br. J. Pharmacol (1993) 108:11–12.
   PubMed Web of Science ®Google Scholar
• SHEPHEARD SL, WILLIAMSON DJ, WILLIAMS J, HILL RG, HARGREAVES RJ: Comparison of the effects of suma-triptan and the NKi antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expres-sion in trigeminal nucleus caudalis of rats. Neurophar-macology (1995) 34(3):255–261.
   PubMedGoogle Scholar
• BEATTIE DT, BERESFORD IJ, CONNOR HE et al.: The pharmacology of GR203040, a novel, potent and selec-tive non-peptide tachykinin NK1 receptor antagonist. Br. J. Pharmacol. (1995) 116(8):3149–3157.
   Google Scholar
• PHEBUS LA, JOHNSON KW, STENGEL PW et al: The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. Life ScL (1997) 60 (18) :1553–1561.
   PubMedGoogle Scholar
• DIENER HC, FOR THE RPR 100,893-201 MIGRAINE STUDY GROUP: Substance P antagonist RPR 100,893-201 is not effective in human migraine attacks. 6th International Headache Research Seminar. Copenhagen, Denmark (1995). Poster 1.
   Google Scholar
• RUPNIAK NMJ, TATTERSALL FD, WILLIAMS AR et al: In vi-tro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists. Eur. J. Pharmacol (1997) 326:201–209.
   Google Scholar
• ••Compares the brain penetration of several lead compounds.
   Google Scholar
• GOLDSTEIN DJ, WANG O, SAPER JR, STOLTZ R, SILBER-STEIN SD, MATHEW NT: Ineffectiveness of neurokinin-1 antagonist in acute migraine: a cross-over study. Cephalagia (1997) 17(7):785–790.
   PubMed Web of Science ®Google Scholar
• LONGMORE J, HILL, RG, HARGREAVES RJ: Neurokinin-receptor antagonists: pharmacological tools and therapeutic drugs. Can. J. Physiol. Pharmacol. (1997) 75 (6):612–621.
   Google Scholar
• •Very good neurokinin review.
   Google Scholar
• CONNOR H, BERTIN L, GILLIES S, BEATTIE DT, WARD P:Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist. Cephalagia (1998) 18:392.9.2.
   Google Scholar
• HALE JJ, MILLS SG, MACCOSS M et al: Structural optimi-sation affording 2 (R)-(1- (R)-3,5-bis(trifluoro-methyl)phenylethoxy)-3- (S)-(4-fluoro)pheny1-4-(3-o xo-1,2,4-triazol-5-yOmethylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J. Med. Chem. (1998) 41:4607–4614.
   Google Scholar
• •SAR of the morpholine acetal class of NK1 antagonist.
   Google Scholar
• NORMAN B, PANEBIANCO D, BLOCK GA: A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine. Cephalagia (1998) 18:407. P42.
   Google Scholar
• MARKOWITZ S, SAITO K, MOSKOWITZ MA: Neurogeni-rally mediated leakage of plasma protein occurs from blood vessels in the dura mater but not brain. J. Neuro-sci. (1980) 7:4129–4136.
   Google Scholar
• NISSILA M, PARKKOLA R, SONNINEN P et al.: Intracere-bral arteries and gadolinium enhancement in mi-graine without aura. Cephalagia (1996) 16: 363.
   Google Scholar
• JOOS GF, VAN SCHOOR J, KIPS JC, PAUWELS RA: The ef-fect of inhaled FK224, a tachykinin NK1 and NK2 recep-tor antagonist, on neurokinin-A-induced bronchoconstriction in asthmatics. Am. J. Respir. Grit. Care Med. (1996) 153:1781–1784.
   PubMed Web of Science ®Google Scholar
• FAHY JV, WONG HH, GEPPETTI P et al.: Effect of an NK1receptor antagonist (CP-99,994) on hypertonic saline-induced bronchoconstriction and cough in male asth-matic subjects. Am. J. Respir. Crit. Care Med. (1995) 152:879–884.
   Google Scholar
• ICHINOSE M, MOTOHIKO M, YAMAUCHI H et al: A neu-rokinin 1-receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. Am. J. Respir. Crit. Care Med. (1996) 153:936–941.
   Google Scholar
• •First report of anti-asthmatic activity by a selective NK1 an-tagonist in the clinic.
   Google Scholar
• VAN SCHOOR J, JOOS GF, CHASSON BL, BROUARD RJ, PAUWELS RA: The effect of the NK2 tachykinin recep-tor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics. Eur. Respir. J. (1998) 12(1):17–23.
   Google Scholar
• •First report of anti-asthmatic activity by a selective NK2 an-tagonist in the clinic.
   Google Scholar
• GARDNER CJ, TWISSELL DJ, DALE TJ et al: The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR 203040. Br. J. Pharmacol. (1995) 116:3158–3163.
   Google Scholar
• KRIS MG, RADFORD J, PIZZO B et al.: Dose-ranging antie-metic trial of the NK-1 receptor antagonist CP-122,721: a new approach for acute and delayed emesis follow-ing cisplatin. Proc. Am. Soc. Clin. Oncol. (1996) 15:A1780.
   Google Scholar
• •First report of activity against delayed emesis in the clinic by NK1 antagonist.
   Google Scholar
• GESZTESI ZS, SONG D, WHITE PF: Comparison of a new NK-1 antagonist (CP-122,721) to ondansetron in the prevention of post-operative nausea and vomiting. An-esth. Anal. (1998) 86:S32.
   Google Scholar
• HESKETH PJ, GRALLA RJ, WEBB RT, UENO W, SILBERMAN S: Randomised Phase II study of the neurokinin-1 an-tagonist CJ-11,974 for the control of cisplatin-induced emesis. Proc. Am. Soc. Clin. Oncol (1998) 17:A19.
   Google Scholar
• NAVARI R, REINHARDT RR, GRALLA RJ et al.: Reduction of cisplatin-induced emesis by a selective neurokinin-1 antagonist. New Engl. J. Med. (1999) 340:190–195.
   Google Scholar
• DIEMUNCH P, SCHOEFFLER P, BRYSSINE B, MULLER LEC, LEES J, MCQUADE B, SPRAGGS C: Anti-emetic activity of the NK-1 antagonist GR205171 in the treatment of PONV following major gynaecological surgery. Anesth. Anal. (1998) 86:S436.
   Google Scholar
• SUAREZ GA, OPFER-GEHRKING TL, MACLEAN DB, LOW PA: Double-blind, placebo-controlled study of the effi-cacy of a substance P (NK1) receptor antagonist in painful peripheral neuropathy. Neurology (1994) 44 (Suppl. 2) :373P.
   Google Scholar
• DIONNE RA, MAX MB, PARADA S, GORDON SM, MA-CLEAN DB: Evaluation of a neurokinin-1 antagonist, CP-99,994, in comparison to ibuprofen and placebo in the oral surgery model. Clin. Pharmacol Ther. (1996) 59 (2) :216.
   Google Scholar
• REINHARDT RR, LAUB JB, FRICKE JR, POLIS AB, GERTZ BJ: Comparison of a neurokinin-1 antagonist, L-754,030, to placebo, acetaminophen and ibuprofen in the den-tal pain model. Clin. Pharmacol. Ther. (1998) P1–124.
   Google Scholar
• BLOCK GA, RUED, PANEBIANCO D, REINES SA: The sub-stance P receptor antagonist L-754,030 (MK-869) is in-effective in the treatment of postherpetic neuralgia. Neurology (1998) 50:A225.
   Google Scholar
• KRAMER MS, CUTLER N, FEIGHNER J et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 281: 1640.
   PubMed Web of Science ®Google Scholar
• ••Substance P antagonist equipotent with SSRI in depression.
   Google Scholar
• QI H, SHAH SK, CASCIREI MA, SADOWSKI SJ, MACCOSS M: t-Tryptophan urea amides as NK1/NK2 dual antago- nists. Bioorg. Med. Chem. Lett. (1998) 8:2259–2262.
   PubMedGoogle Scholar